Provectus Pharma (PVCT) 2.3700 $PVCT
Brendan O'Brien Named to Strategic Advisory Board of Provectus Biopharmaceuticals, Inc.
ACCESSWIRE - Tue May 06, 9:38AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT), a biotech company specializing in developing oncology and dermatology therapies, announced today the appointment of Brendan O'Brien to its strategic advisory board.
Provectus Biopharmaceuticals names Brendan O'Brien to strategic advisory board
M2 - Tue May 06, 6:03AM CDT
Biopharmaceutical company Provectus Biopharmaceuticals (Other OTC
VCT) revealed on Tuesday the addition of Brendan O'Brien to its strategic advisory board.
Cellceutix Corp. Reports Favorable Results on Trial of New Antibiotic
ACCESSWIRE - Mon Apr 28, 8:07AM CDT
Cellceutix Corp. (OTCQB: CTIX) enjoyed strong stock volume Apr. 25, with 180,001 shares changing hands.
Provectus Biopharmaceuticals, Inc. Retains Roberti+White, LLC as Public Policy Consultants
Business Wire - Mon Apr 28, 7:49AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it has retained the services of Roberti+White, LLC as its public policy consultants.
OncoSec Medical Appoints New Executive Director of Research and Development
ACCESSWIRE - Tue Apr 22, 10:09AM CDT
OncoSec Medical Inc.'s (OTCQB: ONCS) share volume was strong Apr. 21 with 2,910,820 shares changing hands.
Provectus' PV-10 Clinical Data on the Treatment of Melanoma to Be Presented at 10th European Association of Dermato-Oncology Congress
Business Wire - Mon Apr 21, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that Dr. Sanjiv Agarwala of St. Luke's University Health Network will present clinical data on Provectus' PV-10 preparation for the treatment of melanoma at the 10th European Association of Dermato-Oncology (EADO) Congress in Vilnius, Lithuania. The Congress runs from May 7-10, 2014, and Dr. Agarwala's presentation is scheduled for the first day of the Congress, Wednesday, May 7.
Elite Pharmaceuticals to Receive up to 40 Million from Lincoln Park Capital Fund
ACCESSWIRE - Tue Apr 15, 9:01AM CDT
Elite Pharmaceuticals Inc. (OTCBB: ELTP) announced Apr. 14 that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund LLC ("LPC"
, a Chicago-based institutional investor for up to $40 million.
Provectus Biopharmaceuticals Signs Agreement with China's Tririver Capital
Business Wire - Mon Apr 14, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it has entered into an advisory agreement with China's Tririver Capital to help identify distribution and joint venture partners for the Company's novel oncology drug PV-10 in China, as well as other therapeutics that Provectus is developing.
Induction of Systemic Immunity Following Treatment of Tumors with PV-10 Reported by Moffitt Cancer Center Researchers at American Association for Cancer Research Annual Meeting
Business Wire - Mon Apr 07, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that a poster presentation detailing significant decrease in melanoma cells in patients' injected tumors 7-14 days after intralesional PV-10 treatment that was accompanied by similar decrease in uninjected bystander tumors was presented April 6 by researchers from the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in San Diego, CA. These clinical and pathologic changes were accompanied by increases in important immune cell populations detected in the patients' peripheral blood.
Provectus Biopharmaceuticals' PV-10 Data to Feature in Poster Presentation by Moffitt Cancer Center at the American Society of Clinical Oncology (ASCO) Annual Meeting
Business Wire - Wed Apr 02, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational drug PV-10 will be featured in a presentation by investigators from Moffitt Cancer Center in a Poster Highlights Session of the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place, Chicago, IL, May 30-June 3, 2014. The time and date of the presentation are expected to become available on the ASCO website, http://am.asco.org, on April 21, 2014.
Provectus Biopharmaceuticals' PV-10 Data to Be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
Business Wire - Tue Apr 01, 5:30AM CDT
--McCormick Place in Chicago, IL, May 30-June 3, 2014
Provectus Biopharmaceuticals' PV-10 Data to Be Presented at the HemOnc Today Melanoma and Cutaneous Malignancies Conference
Business Wire - Tue Apr 01, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that data on PV-10 for cutaneous melanoma will be included in a session at HemOnc Today - Melanoma and Cutaneous Malignancies Conference. HemOnc Today will be held this year at the Sheraton New York Times Square in New York City on Friday, April 11 and Saturday, April 12, 2014.
Provectus Biopharmaceuticals expects US FDA's Breakthrough Therapy Designation for PV-10 for melanoma within 60 days of receipt of application
M2 - Tue Mar 25, 6:14AM CDT
Biopharmaceutical company Provectus Biopharmaceuticals (Other OTC VCT) said on Monday that it has submitted an application for PV-10 for the treatment of melanoma under the US FDA's Breakthrough Therapy Designation (BTD).
Provectus Biopharmaceuticals Inc. Submits Application to FDA to Receive Breakthrough Therapy Designation for PV-10 for Treatment of Melanoma
Business Wire - Mon Mar 24, 5:05AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it has applied to the FDA for Breakthrough Therapy Designation (BTD) for PV-10 for the treatment of melanoma. FDA guidelines state that the Agency will make a decision on the application within 60 days of receipt. The Agency's records for FY 2013 show that the Agency's Center for Drug Evaluation and Research (CDER) met that guideline 97% of the time.
Provectus names Dr Joseph M. Chalil to strategic advisory board
M2 - Thu Mar 20, 8:20AM CDT
Oncology company Provectus Biopharmaceuticals (Other OTC VCT) disclosed on Wednesday that Dr Joseph M. Chalil, MD, MBA, FACHE, has been elected to its strategic advisory board.
Provectus names Dr Joseph M. Chalil to Strategic Advisory Board
M2 - Wed Mar 19, 8:34AM CDT
Provectus Biopharmaceuticals, Inc. (OTC: PVCT), a development-stage oncology and dermatology biopharmaceutical company, today announced the appointment of Dr Joseph M. Chalil to its strategic advisory board.
Provectus Pharmaceuticals, Inc. Melanoma Version of PV-10 Completes Phase 2 and is Prepping for BTD
PR Newswire - Thu Mar 13, 11:04AM CDT
Provectus Pharmaceuticals, Inc. (OTC: PVCT) The melanoma version of the drug is the closest to market release. Phase 2 data was finalized in October 2012 and the drug is being prepped for Breakthrough Therapy Designation (BTD) Drug Submission with the FDA and is in the final steps for approval. Once submitted PVCT should receive a decision within 60 days of receipt of that request.
Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.
Brendan O'Brien Named to Strategic Advisory Board of Provectus Biopharmaceuticals, Inc.
ACCESSWIRE - Tue May 06, 9:38AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT), a biotech company specializing in developing oncology and dermatology therapies, announced today the appointment of Brendan O'Brien to its strategic advisory board.
Provectus Biopharmaceuticals names Brendan O'Brien to strategic advisory board
M2 - Tue May 06, 6:03AM CDT
Biopharmaceutical company Provectus Biopharmaceuticals (Other OTC
VCT) revealed on Tuesday the addition of Brendan O'Brien to its strategic advisory board. Cellceutix Corp. Reports Favorable Results on Trial of New Antibiotic
ACCESSWIRE - Mon Apr 28, 8:07AM CDT
Cellceutix Corp. (OTCQB: CTIX) enjoyed strong stock volume Apr. 25, with 180,001 shares changing hands.
Provectus Biopharmaceuticals, Inc. Retains Roberti+White, LLC as Public Policy Consultants
Business Wire - Mon Apr 28, 7:49AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB
VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it has retained the services of Roberti+White, LLC as its public policy consultants. OncoSec Medical Appoints New Executive Director of Research and Development
ACCESSWIRE - Tue Apr 22, 10:09AM CDT
OncoSec Medical Inc.'s (OTCQB: ONCS) share volume was strong Apr. 21 with 2,910,820 shares changing hands.
Provectus' PV-10 Clinical Data on the Treatment of Melanoma to Be Presented at 10th European Association of Dermato-Oncology Congress
Business Wire - Mon Apr 21, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB
VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that Dr. Sanjiv Agarwala of St. Luke's University Health Network will present clinical data on Provectus' PV-10 preparation for the treatment of melanoma at the 10th European Association of Dermato-Oncology (EADO) Congress in Vilnius, Lithuania. The Congress runs from May 7-10, 2014, and Dr. Agarwala's presentation is scheduled for the first day of the Congress, Wednesday, May 7. Elite Pharmaceuticals to Receive up to 40 Million from Lincoln Park Capital Fund
ACCESSWIRE - Tue Apr 15, 9:01AM CDT
Elite Pharmaceuticals Inc. (OTCBB: ELTP) announced Apr. 14 that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund LLC ("LPC"
, a Chicago-based institutional investor for up to $40 million. Provectus Biopharmaceuticals Signs Agreement with China's Tririver Capital
Business Wire - Mon Apr 14, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB
VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it has entered into an advisory agreement with China's Tririver Capital to help identify distribution and joint venture partners for the Company's novel oncology drug PV-10 in China, as well as other therapeutics that Provectus is developing. Induction of Systemic Immunity Following Treatment of Tumors with PV-10 Reported by Moffitt Cancer Center Researchers at American Association for Cancer Research Annual Meeting
Business Wire - Mon Apr 07, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB
VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that a poster presentation detailing significant decrease in melanoma cells in patients' injected tumors 7-14 days after intralesional PV-10 treatment that was accompanied by similar decrease in uninjected bystander tumors was presented April 6 by researchers from the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in San Diego, CA. These clinical and pathologic changes were accompanied by increases in important immune cell populations detected in the patients' peripheral blood. Provectus Biopharmaceuticals' PV-10 Data to Feature in Poster Presentation by Moffitt Cancer Center at the American Society of Clinical Oncology (ASCO) Annual Meeting
Business Wire - Wed Apr 02, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB
VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational drug PV-10 will be featured in a presentation by investigators from Moffitt Cancer Center in a Poster Highlights Session of the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place, Chicago, IL, May 30-June 3, 2014. The time and date of the presentation are expected to become available on the ASCO website, http://am.asco.org, on April 21, 2014. Provectus Biopharmaceuticals' PV-10 Data to Be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
Business Wire - Tue Apr 01, 5:30AM CDT
--McCormick Place in Chicago, IL, May 30-June 3, 2014
Provectus Biopharmaceuticals' PV-10 Data to Be Presented at the HemOnc Today Melanoma and Cutaneous Malignancies Conference
Business Wire - Tue Apr 01, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB
VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that data on PV-10 for cutaneous melanoma will be included in a session at HemOnc Today - Melanoma and Cutaneous Malignancies Conference. HemOnc Today will be held this year at the Sheraton New York Times Square in New York City on Friday, April 11 and Saturday, April 12, 2014. Provectus Biopharmaceuticals expects US FDA's Breakthrough Therapy Designation for PV-10 for melanoma within 60 days of receipt of application
M2 - Tue Mar 25, 6:14AM CDT
Biopharmaceutical company Provectus Biopharmaceuticals (Other OTC
VCT) said on Monday that it has submitted an application for PV-10 for the treatment of melanoma under the US FDA's Breakthrough Therapy Designation (BTD). Provectus Biopharmaceuticals Inc. Submits Application to FDA to Receive Breakthrough Therapy Designation for PV-10 for Treatment of Melanoma
Business Wire - Mon Mar 24, 5:05AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB
VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it has applied to the FDA for Breakthrough Therapy Designation (BTD) for PV-10 for the treatment of melanoma. FDA guidelines state that the Agency will make a decision on the application within 60 days of receipt. The Agency's records for FY 2013 show that the Agency's Center for Drug Evaluation and Research (CDER) met that guideline 97% of the time. Provectus names Dr Joseph M. Chalil to strategic advisory board
M2 - Thu Mar 20, 8:20AM CDT
Oncology company Provectus Biopharmaceuticals (Other OTC
VCT) disclosed on Wednesday that Dr Joseph M. Chalil, MD, MBA, FACHE, has been elected to its strategic advisory board. Provectus names Dr Joseph M. Chalil to Strategic Advisory Board
M2 - Wed Mar 19, 8:34AM CDT
Provectus Biopharmaceuticals, Inc. (OTC: PVCT), a development-stage oncology and dermatology biopharmaceutical company, today announced the appointment of Dr Joseph M. Chalil to its strategic advisory board.
Provectus Pharmaceuticals, Inc. Melanoma Version of PV-10 Completes Phase 2 and is Prepping for BTD
PR Newswire - Thu Mar 13, 11:04AM CDT
Provectus Pharmaceuticals, Inc. (OTC: PVCT) The melanoma version of the drug is the closest to market release. Phase 2 data was finalized in October 2012 and the drug is being prepped for Breakthrough Therapy Designation (BTD) Drug Submission with the FDA and is in the final steps for approval. Once submitted PVCT should receive a decision within 60 days of receipt of that request.
Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.
